Traws Pharma, Inc. (TRAW) Form S-1 — Oct 26, 2026
Traws Pharma filed an S-1 to register the resale by Roth Principal Investments of up to 135,135,135 shares of common stock issuable under a $50 million committed equity facility (Purchase Agreement) dated October 23, 2026. Roth will buy shares at 94.0% of VWAP (a 6.0% discount), and Traws controls the timing and amount of any sales. The registered shares equal roughly 879.3% of the 15.37 million shares currently outstanding and would represent about 89.79% of the company if fully issued, against a non-affiliate float valued at only $5.44 million.
Key figures
- Gross Proceeds
- 50000000
- Offering Price
- 0.37
- Shares Offered
- 135135135
- Shares Outstanding
- 15368277
- Qiufee
- $50,000 to Compass Point
- Base price
- 0.3663
- Threshold price
- 0.1
- Exchange cap pct
- 19.99%
- Commitment period
- 36 months
- Purchase discount
- 6.0% to VWAP (94.0% of VWAP or closing price)
- Closing price oct23
- 0.34
- Exchange cap shares
- 3072118
- Estimated net proceeds
- $46.5 million if full commitment drawn
- Legal fee reimbursement
- $100,000 initial plus up to $7,500 per quarter
- Non affiliate float value
- $5,439,274.17
- Beneficial ownership limit
- 4.99%
- Registered shares pct of outstanding
- 879.3%
- Registered shares pct if fully issued
- 89.79%
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.